SenesTech (SNES) 10-Q 14 Nov 18 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 14, 2018
Document And Entity Information
Entity Registrant Name	SenesTech, Inc.
Entity Central Index Key	1,680,378
Trading Symbol	SNES
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		23,452,695
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,019

BALANCE SHEETS (Unaudited)

BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash	$ 4,791	$ 2,101
Investment in securities	2,448	5,023
Accounts receivable	52	16
Prepaid expenses	336	170
Inventory	1,118	540
Deposits	12	19
Total current assets	8,757	7,869
Property and equipment, net	1,171	1,454
Total assets	9,928	9,323
Current liabilities:
Short-term debt	235	177
Accounts payable	206	391
Accrued expenses	531	589
Notes payable, related parties	0	12
Total current liabilities	972	1,169
Long-term debt, net	296	591
Deferred rent	23	41
Total liabilities	1,291	1,801
Commitments and contingencies (See note 14)
Stockholders' equity:
Common stock, $0.001 par value, 100,000,000 shares authorized, 23,425,237 and 16,404,195 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	23	16
Additional paid-in capital	91,822	81,103
Accumulated deficit	(83,208)	(73,597)
Total stockholders' equity	8,637	7,522
Total liabilities and stockholders' equity	$ 9,928	$ 9,323

BALANCE SHEETS (Unaudited) (Par

BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	100,000,000	100,000,000
Common stock shares issued	23,425,237	16,404,195
Common stock shares outstanding	23,425,237	16,404,195

STATEMENTS OF OPERATIONS AND CO

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Net Sales	$ 105	$ 17	$ 160	$ 34
Cost of sales	114	11	153	27
Gross profit (loss)	(9)	6	7	7
Operating expenses:
Research and development	476	721	1,746	2,517
Selling, general and administrative	2,013	2,235	7,506	7,506
Total operating expenses	2,489	2,956	9,252	10,023
Net operating loss	(2,498)	(2,950)	(9,245)	(10,016)
Other income (expense):
Interest income	1	9	8	20
Interest expense	(16)	(33)	(60)	(54)
Interest expense, related parties				(1)
Other income (expense)	13	37	19	76
Total other income (expense)	(2)	13	(33)	41
Net loss and comprehensive loss	(2,500)	(2,937)	(9,278)	(9,975)
Deemed dividend-warrant price protection adjustment	333		333
Net loss attributable to common shareholders	$ (2,833)	$ (2,937)	$ (9,611)	$ (9,975)
Loss per share atrributable to common shareholders, basic and diluted (in dollars per share)	$ (0.14)	$ (0.28)	$ (0.53)	$ (0.97)
Weighted average common shares outstanding - basic and fully diluted (in shares)	20,862,216	10,334,211	18,036,982	10,234,211

STATEMENTS OF CASH FLOWS (Unaud

STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (9,278)	$ (9,975)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on investments	(44)	(20)
Amortization of discounts on investments		11
Depreciation and amortization	332	273
Stock-based compensation	3,090	2,818
Loss on sale of equipment	15
Loss on early extinguishment of debt	10
(Gain) loss on remeasurement of common stock warrant liability	1	(65)
(Increase) decrease in current assets:
Accounts receivable	(36)	3
Prepaid expenses	(166)	165
Inventory	(578)	(337)
Deposits	7	(8)
Increase (decrease) in current liabilities:
Accounts payable	(185)	(176)
Accrued contract cancellation settlement		(1,000)
Accrued expenses	(66)	703
Deferred rent	(18)	12
Net cash used in operating activities	(6,916)	(7,596)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of securities		(2,940)
Proceeds received on sale of securities	2,619
Proceeds received on sale of equipment	185
Purchase of property and equipment	(212)	(885)
Net cash provided by (used in) investing activities	2,592	(3,825)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the issuance of common stock, net	5,132
Proceeds from the issuance of notes payable	9	437
Repayments of notes payable, net	(236)	(48)
Repayments of notes payable, related parties	(12)	(18)
Repayments of capital lease obligations	(50)	(77)
Proceeds from the exercise of warrants	2,213
Payment of employee withholding taxes relating to share-based awards	(42)
Net cash provided by financing activities	7,014	294
NET CHANGE IN CASH	2,690	(11,127)
CASH AT BEGINNING OF PERIOD	2,101	11,826
CASH AT END OF PERIOD	4,791	699
SUPPLEMENTAL INFORMATION:
Interest paid	60	55
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Deemed dividend	333
Purchases of equipment under capital lease obligations	$ 37	$ 316

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Note 1 - Organization and Description of Business SenesTech, Inc. (“SenesTech,” the “Company,” “we” or “us”) was formed in July 2004 and incorporated in the state of Nevada. The Company subsequently reincorporated in the state of Delaware in November 2015. Our corporate headquarters is in Flagstaff, Arizona. We have developed and are commercializing a global, proprietary technology for managing animal pest populations, primarily rat populations, through fertility control. Pest management professionals ("PMPs") continue to face challenges in controlling infestations. While there are many tools to bring rat populations down quickly, they are at a disadvantage: they do not prevent the rapid reproduction, leaving PMPs and their customers open to a possible rebound in rat population. ContraPest ® Additionally, PMPs are being increasingly asked for new solutions to help them solve their customers’ toughest rat infestations. With growing interest in non-lethal options, it is becoming increasingly important for PMPs to have proven non-lethal tools at their disposable. ContraPest can help PMPs expand their service offering and serve customers that are looking to decrease or eliminate the amount of lethal rat control methodologies. Our flagship fertility control product, ContraPest is a liquid fertility control bait containing the active ingredients 4-vinylcyclohexene diepoxide (“VCD”) and triptolide. When consumed, ContraPest targets reproduction, limiting fertility in male and female Norway and roof rats beginning with initial consumption. ContraPest can be deployed in either the JT Eaton Rat Fortress (903TP) or the Bell Labs EVO PROTECA Express bait stations, giving PMPs flexibility in their site deployments. We submitted ContraPest for registration with the EPA on August 23, 2015, and the EPA granted registration approval for ContraPest effective August 2, 2016. We expect to continue to pursue regulatory approvals and amendments to existing registration in the United States for ContraPest, including additional species and additional jurisdictions. We believe ContraPest is the first and only non-lethal, fertility control product approved by the EPA for the management of rat populations. In addition to the EPA registration of ContraPest in the U.S., we must obtain registration from the various state regulatory agencies prior to being used in each state. We have received registration for ContraPest in all 50 states and the District of Columbia. The EPA also approved the removal of Restricted Use Pesticide ("RUP") designation from the ContraPest ® Besides providing just the product, SenesTech provides PMPs with product training, and supports the PMPs by creating tools, training and awareness campaigns to help inform their customers, specifically within the food safety industry and larger residential customers, such as Home Owners Associations (“HOAs”), on the benefits of including ContraPest into their IPM protocols. *When used as directed. ContraPest ® Potential Need for Additional Capital Since our inception, we have sustained significant operating losses in the course of our research and development activities, and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under our former license agreement with Neogen. In 2017, we began to prepare and launch commercialization of our first product, ContraPest. We have funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock. Such sales include: (i) an initial public offering of 1,875,000 shares of our common stock on December 8, 2016 with warrants to purchase an additional 187,500 shares issued to Roth Capital Partners, LLC with an exercise price of $9.60 per share, as underwriter, (ii) a public offering on November 21, 2017 of 5,860,000 shares of our common stock at $1.00 per share with warrants issued to investors to purchase an additional 4,657,500 shares of our common stock with an initial exercise price of $1.50 per share that subsequently adjusted downward to $0.95 per share pursuant to antidilution price protection contained within those warrants, and warrants issued to Roth Capital Partners, LLC, as underwriter, to purchase an additional 945,000 shares with an exercise price of $1.50 per share, (iii) a private placement of warrants to purchase 1,133,909 shares of common stock in June 2018 with an exercise price of $1.82 per share in connection with an inducement agreement with a holder of outstanding warrants issued in November 2017 to exercise its original warrant representing 1,133,909 shares at an exercise price of $1.50 per share; and (iv) a rights offering in August 2018 (the “Rights Offering”), where we accepted subscriptions for 5,357,052 units for a purchase price of $1.15 per unit, with each unit consisting of one share of our common stock and one warrant, with each warrant exercisable for one share of our common stock at an exercise price of $1.15 per share., and warrants issued to an affiliate of Maxim Group, LLC, as dealer-manager, to purchase an additional 267,853 shares at $1.725 per share We have also raised capital through debt financing, consisting primarily of convertible notes; and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees Through September 30, 2018, we had received net proceeds of $61.7 million from our sales of common stock, preferred stock and warrant exercises and issuance of convertible and other promissory notes, an aggregate of $1.7 million from licensing fees and an aggregate of $0.2 million in product sales. At September 30, 2018, we had an accumulated deficit of $83.2 million and cash and cash equivalents and highly liquid investments of $7.2 million. Our ultimate success depends upon the outcome of a combination of factors, including: (i) successful commercialization of ContraPest and ongoing regulatory approvals of our other product candidates encompassing market acceptance, commercial viability and profitability of ContraPest and other products; (ii) our ability to retain and attract key personnel to develop, operate and grow our business; and (iii) our ability to meet our working capital needs. Based upon our current operating plan, we expect that cash and cash equivalents and highly liquid, short term investments at September 30, 2018, in combination with anticipated revenue, will be sufficient to fund our current operations for at least the next 12 months. However, if anticipated revenue targets and margin targets are not achieved, we may seek to reduce operating expenses and are likely to require additional capital in order to fund our operating losses and research and development activities until we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts. Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the Company’s opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2018, the Company’s operating results for the three and nine months ended September 30, 2018 and 2017, and the Company’s cash flows for the nine months ended September 30, 2018 and 2017. The accompanying financial information as of December 31, 2017 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K, as amended for the year ended December 31, 2017. All amounts shown in these financial statements and accompanying notes are in thousands, except percentages and per share and share amounts.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in the Company’s financial statements include the valuation of preferred stock, common stock and related warrants, and other stock-based awards. Actual results could differ from such estimates. Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no material impact on net earnings, financial position or cash flows. Cash and Cash Equivalents The Company considers money market fund investments to be cash equivalents. The Company had such cash equivalents of $21 and $3 at September 30, 2018 and December 31, 2017, respectively, included in cash as reported. Investments in Securities The Company uses cash holdings to purchase highly liquid, short term, investment grade securities diversified among security types, industries and issuers. All of the Company’s investment securities are measured at fair value. The Company’s investment securities primarily consist of municipal debt securities, corporate bonds, U.S. agency securities and commercial paper and highly-liquid money market funds. Accounts Receivable Accounts receivable consist entirely of trade receivables. The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. The allowance for doubtful trade receivables was less than $1 as of September 30, 2018 and $0 at December 31, 2017. Deferred Offering Costs Deferred offering costs consisted primarily of legal, accounting and other direct and incremental fees and costs related to the Rights Offering that closed on August 13, 2018 and the downward price adjustment that occurred to certain outstanding warrants as a result of the Rights Offering. Total deferred offering costs of $1.0 million were offset against the proceeds received from the Rights Offering during the quarter ending September 30, 2018. There were no deferred offering costs at September 30, 2018 or December 31, 2017. Inventories Inventories are stated at the lower of cost or market value, using the first-in, first-out convention. Inventories consist of raw materials, work in process and finished goods. Prepaid Expenses Prepaid expenses consist primarily of payments made for director compensation as well as payments made for director and officer insurance, rent and legal deposits to be expensed in the current year. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Equipment held under capital leases are stated at the present value of minimum lease payments less accumulated amortization. Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. The cost of leasehold improvements is amortized over the life of the improvement or the term of the lease, whichever is shorter. Equipment held under capital leases is amortized over the shorter of the lease term or estimated useful life of the asset. The Company incurs repair and maintenance costs on its major equipment, which are expensed as incurred. Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require long-lived assets or asset groups to be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated from the use of the asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, such as discounted cash flow models and the use of third-party independent appraisals. The Company has not recorded an impairment of long-lived assets since its inception. Revenue Recognition Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Revenue Recognition. Revenue Recognition The Company recognizes revenue when it leaves their facility at a fixed selling price and payment terms of 30 to 60 days from invoicing. All of the revenue recognized in the three month and nine month periods ended September 30, 2018 and 2017 is from the sale of Contrapest. Research and Development Research and development costs are expensed as incurred. Research and development expenses primarily consist of salaries and benefits for research and development employees, stock-based compensation, consulting fees, lab supplies, costs incurred related to conducting scientific trials and field studies, and regulatory compliance costs. Also, included in research and development expenses is an allocation of facilities related costs, including depreciation of research and development equipment. Stock-based Compensation Employee stock-based awards, consisting of restricted stock units and stock options expected to be settled in shares of the Company’s common stock, are recorded as equity awards. The grant date fair value of these awards is measured using the Black-Scholes option pricing model. The Company expenses the grant date fair value of its stock options on a straight-line basis over their respective vesting periods. Performance-based awards are expensed over the performance period when the related performance goals are probable of being achieved. For equity instruments issued to non-employees, the stock-based consideration is measured using a fair value method. The measurement of the stock-based compensation is subject to re-measurement as the underlying equity instruments vest. The stock-based compensation expense recorded for the three and nine months ended September 30, 2018 and 2017, is as follows: Three Months Ended Nine Months Ended 2018 2017 2018 2017 Research and development $ 29 $ 85 $ 87 $ 269 Selling, general and administrative 326 861 3,003 2,549 Total stock-based compensation expense $ 355 $ 946 $ 3,090 $ 2,818 See Note 13 for additional discussion on stock-based compensation. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities and net operating loss carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. These deferred tax assets are subject to periodic assessments as to recoverability and if it is determined that it is more likely than not that the benefits will not be realized, valuation allowances are recorded which would increase the provision for income taxes. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. The Company applies a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities are recognized. Based on its evaluation, the Company has concluded there are no significant uncertain tax positions requiring recognition in its financial statements. The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There are no uncertain tax positions as of September 30, 2018 or December 31, 2017 and as such, no interest or penalties were recorded in income tax expense. On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) which provides guidance on accounting for the tax effects of the Tax Cuts and Job Act of 2017 (the “Tax Act”). SAB 118 provides a measurement period that should not extend beyond one year from the date of enactment for companies to complete the accounting under ASC 740, Income Taxes. The Company is still analyzing the Tax Act and the impact, if any, it will have. Comprehensive Loss Net loss and comprehensive loss were the same for all periods presented; therefore, a separate statement of comprehensive loss is not included in the accompanying financial statements. Loss Per Share Attributable to Common Stockholders Basic loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share attributable to common stockholders is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods. For purposes of the computation of diluted loss per share attributable to common stockholders, common stock purchase warrants, and common stock options are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share attributable to common stockholders because their effect would be anti-dilutive given the net loss reported for the three and nine months ended September 30, 2018 and 2017. Therefore, basic and diluted loss per share attributable to common stockholders are the same for each period presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted loss per share attributable to common stockholders (in common stock equivalent shares): September 30, 2018 2017 Common stock purchase warrants 11,714,940 829,285 Restricted stock units 172,912 344,982 Common stock options 1,725,771 1,558,800 Total 13,613,623 2,733,067 Adoption of New Accounting Standards: In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers “Revenue from Contracts with Customers” Revenue Recognition In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities Accounting Standards Issued But Not Yet Adopted: In February 2016, the FASB issued ASU 2016-02, Leases

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 3 - Fair Value Measurements We invest in various short term, highly liquid financial instruments, which may include municipal debt securities, corporate bonds, U.S. agency securities and commercial paper. We value these instruments at fair value. The accounting guidance for fair value, among other things, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The framework for measuring fair value consists of a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows: Level 1 Level 2 Level 3 An asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques: A. Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. B. Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost). C. Income approach: Techniques to convert future amounts to a single present amount based upon market expectations, including present value techniques, option-pricing and excess earnings models. The Company’s cash equivalents, which include money market funds, are classified as Level 1 because they are valued using quoted market prices. The Company’s marketable securities consist of securities and are generally classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. In certain cases where there is limited activity or less transparency around the inputs to valuation, securities are classified as Level 3. Level 3 liabilities consist of common stock warrant liability. Items Measured at Fair Value on a Recurring Basis The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy: September 30, 2018 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 21 $ — $ — $ 21 Corporate fixed income debt securities — 2,448 — 2,448 Total $ 21 $ 2,448 $ — $ 2,469 Financial Liabilities: Common stock warrant liability (1) $ — $ — $ — $ — Total $ — $ — $ — $ — December 31, 2017 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 3 $ — $ — $ 3 Corporate fixed income debt securities — 5,023 — 5,023 Total $ 3 $ 5,023 $ — $ 5,026 Financial Liabilities: Common stock warrant liability (1) $ — $ — $ — $ — Total $ — $ — $ — $ — (1) The change in the fair value of the common stock warrant and convertible notes payable for the three and nine months ended September 30, 2018 was recorded as a decrease to other income (expense) and interest expense of $1 and $1, respectively, in the statements of operations and comprehensive loss. Financial Instruments Not Carried at Fair Value The carrying amounts of the Company’s financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities. The estimated fair value of notes payable, not recorded at fair value, are recorded at cost or amortized cost which was deemed to estimate fair value.

Investments in Securities

Investments in Securities	9 Months Ended
	Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]
Investments In Securities Held To Maturity	Note 4 - Investments in Securities As of September 30, 2018, investment in securities primarily consisted of corporate fixed income securities These investments are in short term, highly liquid investments which are recorded at cost plus or minus market fluctuation and gains and losses are recognized as the sale or redemption of the securities is realized. Gains and losses are included in non-operating other income (expense) on the condensed statement of operations and are derived using the specific identification method for determining the cost of the securities sold. For the three and nine months ended September 30, 2018, the Company recorded $12 and $44 net gain (loss) on investments recorded, respectively. Interest and dividends on investment securities are included in interest and other income, net, in the condensed statements of operations. The following is a summary of investment in securities at September 30, 2018: September 30, 2018 Contractual Maturity (in months) Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Mutual funds $ — $ — $ — $ — Corporate fixed income securities Less than 12 months 2,447 1 — 2,448 Total investments $ 2,447 $ 1 $ — $ 2,448

Prepaid Expenses

Prepaid Expenses	9 Months Ended
	Sep. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	Note 5 - Prepaid Expenses Prepaid expenses consist of the following: September 30, December 31, 2018 2017 Director compensation $ 156 $ 66 Director and officer insurance 102 33 NASDAQ fees 14 — Legal retainer 25 25 Inventory purchase deposits 20 20 Professional services retainer 8 8 Equipment service deposits 5 7 Engineering, software licenses and other 6 11 Total prepaid expenses $ 336 $ 170

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 6 - Property and Equipment Property and equipment, net consist of the following: Useful September 30, December 31, Life 2018 2017 Research and development equipment 5 years $ 1,540 $ 1,349 Office and computer equipment 3 years 730 672 Autos 5 years 54 305 Furniture and fixtures 7 years 34 34 Leasehold improvements * 283 283 2,641 2,643 Less accumulated depreciation (1,470 ) (1,189 ) Total $ 1,171 $ 1,454 * Shorter of lease term or estimated useful life Depreciation expense was approximately $108 and $118 for the three months ended September 30, 2018 and 2017, respectively, and $332 and $272 for nine months ended September 30, 2018 and 2017, respectively.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Accrued Expenses	Note 7 - Accrued Expenses Accrued expenses consist of the following: September 30, December 31, 2018 2017 Compensation and related benefits $ 217 $ 304 Accrued Litigation 269 269 Board Compensation — 16 Stock service fees 23 — Delaware Franchise Tax-Other 22 — Total accrued expenses $ 531 $ 589

Borrowings

Borrowings	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Borrowings	Note 8 - Borrowings A summary of the Company’s borrowings, including capital lease obligations, is as follows: September 30, December 31, Short-term debt: 2018 2017 Current portion of long-term debt 235 177 Total short-term debt $ 235 $ 177 Long-term debt: Capital lease obligations $ 252 $ 272 Other promissory notes 279 496 Total 531 768 Less: current portion of long-term debt (235 ) (177 ) Total long-term debt $ 296 $ 591 Capital Lease Obligations Capital lease obligations are for computer and lab equipment leased through GreatAmerica Financial Services, Thermo Fisher Scientific, Navitas Credit Corp., Wells Fargo and ENGS Commercial Finance Co. These capital leases expire at various dates through July 2023 and carry interest rates ranging from 6.0% to 11.6%. Other Promissory Notes Also included in the table above are three notes payable to Direct Capital, one note to M2 Financing and one note to Fidelity Capital, all for the financing of fixed assets. These notes expire at various dates through June 2022 and carry interest rates ranging from 4.3% to 13.8%.

Notes Payable, Related Parties

Notes Payable, Related Parties	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Notes Payable, Related Parties	Note 9 - Notes Payable, Related Parties A summary of the Company’s notes payable, related parties is as follows: September 30, December 31, 2018 2017 Unsecured promissory note, interest rate of 4.25% and 8% per annum $ 0 $ 12 Total notes payable, related parties 0 12 Less: current portion of notes payable, related parties 0 12 Total notes payable, long-term $ — $ — In April 2013, the Company and a previous employee entered into an agreement to settle all outstanding obligations consisting of a promissory note of $40, dated March 2009, and deferred salaries amounting to $72. The note and salary obligation had an interest at 8% and 4.25%, respectively. The note required monthly payments of $1 and matured in May 2018, but the final disbursement was not made until July 2018. The deferred salary obligation required monthly payments of $1 and matured in June 2018, with final payment also made in July 2018. Amounts outstanding on these obligations were $0 and $12 at September 30, 2018 and December 31, 2017, respectively. Interest expense on the notes payable, related parties, was $0 for each of the three and nine months ended September 30, 2018 and $1 for the year ended December 31, 2017 respectively.

Common Stock Warrants and Commo

Common Stock Warrants and Common Stock Warrant Liability	9 Months Ended
	Sep. 30, 2018
Warrants and Rights Note Disclosure [Abstract]
Common Stock Warrants and Common Stock Warrant Liability	Note 10 - Common Stock Warrants and Common Stock Warrant Liability The table summarizes the common stock warrant activity as of September 30, 2018 as follows: Number of Date Exercise Common Stock Warrants Warrants Issued Term Price Outstanding at December 31, 2016 829,285 Common Stock Offering Warrants Issued 4,657,500 November 2017 5 years $ 1.50 (1) Common Stock Offering Underwriter Warrants 945,000 November 2017 5 years $ 1.50 Outstanding at December 31, 2017 6,431,785 Warrants issued 1,133,909 June 2018 5 years $ 1.82 Common Stock Offering Warrants Issued 5,357,052 August 2018 5 years $ 1.15 (1) Common Stock Offering - Dealer Manager Warrants 267,853 August 2018 5 years $ 1.725 Warrants exercised (1,475,659) Outstanding at September 30, 2018 11,714,940 (1) The common stock warrants issued in November 2017 with an initial exercise price of $1.50 per share adjusted downward to $0.95 per share effective July 24, 2018 in connection with our Rights Offering, and may be subject to further downward adjustments, pursuant to antidilution price adjustment protection contained within those warrants. On November 21, 2017, the Company issued a total of 4,657,500 detachable common stock warrants issued with the second public offering of 5,860,000 shares of its common stock at $1.00 per share. The common stock warrant is exercisable until five years from the date of grant. The common shares of the Company’s stock and detachable warrants exist independently as separate securities. As such, the Company estimated the fair value of the common stock warrants, exercisable at $1.50 per share, to be $661 using a lattice model based on the following significant inputs: Common stock price of $1.00; comparable company volatility of 73.8%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 1.87. The initial exercise price of these warrants was $1.50 per share, which adjusted downward to $1.47 on July 24, 2018, the record date of the Right’s Offering and downward to $0.95 per share on August 13, 2018, the date of the Rights Offering, pursuant to antidilution price adjustment protection contained within these warrants. Per guidance of ASC 260, the Company recorded a deemed dividend of $333 on the 3,181,841 unexercised warrants that contained this antidilution price adjustment protection provision and was calculated as the difference between the fair value of the warrants immediately prior to downward exercise price adjustment and immediately after the adjustment using a Black Scholes model based on the following significant inputs: On July 24, 2018: Common stock price of $1.38; comparable company volatility of 72.4%; remaining term 4.33 years; dividend yield of 0% and risk-free interest rate of 2.83%. On August 13, 2018: Common stock price of $1.02; comparable company volatility of 74.0%; remaining term 4.25 years; dividend yield of 0% and risk-free interest rate of 2.75%. On June 20, 2018, the Company entered into an agreement with a holder of 1,133,909 of the November 2017 warrants to exercise its original warrant representing 1,133,909 shares of Common Stock for cash at the $1.50 exercise price for gross proceeds of $1.7 million and the Company issued to holder a new warrant to purchase 1,133,909 shares of Common Stock at an exercise price of $1.82 per share. The new warrant did not contain the antidilution price adjustment protection that was contained within the exercised warrants. In June 2018, the Company recorded stock compensation expense of $1.7 million representing the fair value of the of 1,133,909 inducement warrants issued. The Company estimated the fair value of the common stock warrants, exercisable at $1.82 per share, to be $1.7 million using a Black Scholes model based on the following significant inputs: Common stock price of $2.11; comparable company volatility of 72.6%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 2.8%. Also in June 2018, an additional 341,750 of the November 8, 2017 warrants that were in the money at the time of exercise, were exercised for gross proceeds of $513. On August 13, 2018, in connection with a Rights Offering of 5,357,052 shares of its common stock, the Company issued 5,357,052 warrants to purchase shares of its common stock at an exercise price of $1.15 per share. The Company estimated the fair value of the common stock warrants, exercisable at $1.15 per share, to be $3.6 million using a Monte Carlo model based on the following significant inputs: common stock price of $0.94; comparable company volatility of 159.0%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 2.77%. In connection with the closing of the Rights Offering, the Company issued a warrant to purchase 267,853 shares of common stock to Maxim Partners LLC, an affiliate of the dealer-manager of the Rights Offering. The Company estimated the fair value of the common stock warrants, exercisable at $1.725 per share, to be $169 using a using a Monte Carlo model based on the following significant inputs: common stock price of $0.94; comparable company volatility of 159.0%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 2.77%. Common Stock Warrant Issued to Underwriter of Common Stock Offering In November 2017, the Company issued to Roth Capital Partners, LLC, as underwriter, a warrant to purchase 945,000 shares of common stock at an exercise price of $1.50 per share as consideration for providing services in connection with our common stock offering. The warrant was fully vested and exercisable on the date of issuance. The common stock warrant is exercisable until five years from the date of grant. The Company estimated the fair value of the common stock warrants, exercisable at $1.50 per share, to be $134 using a lattice model based on the following significant inputs: Common stock price of $1.00; comparable company volatility of 73.8%; remaining term 5 years; dividend yield of 0% and risk-free interest rate of 1.87%. University of Arizona Common Stock Warrant In connection with the June 2015 amended and restated exclusive license agreement with the University of Arizona (“University”), the Company issued to the University a common stock warrant to purchase 15,000 shares of common stock at an exercise price of $7.50 per share. The warrant was fully vested and exercisable on the date of grant, and expires, if not exercised, five years from the date of grant. In the event of a “terminating change” of the Company, as defined in the warrant agreement, the warrant holder would be paid in cash the aggregate fair market value of the underlying shares immediately prior to the consummation of the terminating change event. Due to the cash settlement provision, the derivative warrant liability was recorded at fair value and is revalued at the end of each reporting period. The changes in fair value are reported in other income (expense) in the statements of operations and comprehensive loss. The estimated fair value of the derivative warrant liability was $53 at the date of grant. The estimated fair value of the derivative warrant liability was $0 at September 30, 2018. As this derivative warrant liability is revalued at the end of each reporting period, the fair values as determined at the date of grant and subsequent periods was based on the following significant inputs using a Monte Carlo option pricing model: common stock price of $7.91; comparable company volatility of 77.7% of the underlying common stock; risk-free rates of 1.93%; and dividend yield of 0%; including the probability assessment of a terminating change event occurring. The change in fair value of the derivative warrant liability was $0 for the three and nine months ended September 30, 2018 and was recorded in other income (expense) in the accompanying statements of operations and comprehensive loss.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Stockholders' Deficit	Note 11 - Stockholders’ Deficit Common Stock The Company had 23,425,287 and 16,404,195 shares of common stock issued and outstanding as of September 30, 2018 and December 31, 2017, respectively. During the nine months ended September 30, 2018, the Company issued 7,021,092 shares of common stock as follows: ● an aggregate of 5,357,052 shares in connection with a Rights Offering generating net proceeds to the Company of approximately $5.1 million, ● an aggregate of 1,475,659 shares for net proceeds of $2.1 million for the exercise of the Company’s November 2017 warrants (see Note 10 — Common Stock Warrants and Common Stock Warrant Liability for further details), ● 13,900 shares for the cashless exercise of stock options to employees, ● 32,625 shares to a former employee for the net settlement of restricted stock units whose vesting accelerated upon the termination of their employment contract, ● 37,162 shares to a Board member in net settlement of Board compensation totaling $28 and ● 104,694 shares for the net settlement of restricted stock units that vested during the period. Rights Offering On August 13, 2018, the Company closed a Rights Offering. Pursuant to the Rights Offering, the Company accepted subscriptions for 5,357,052 units for a purchase price of $1.15 per unit, with each unit consisting of one share of the Company’s common stock, par value $0.001 per share, and one warrant. Each warrant included in the unit was exercisable for one share of the Company’s common stock at an exercise price of $1.15 per share. At closing of the Rights Offering, the Company issued 5,357,052shares of its common stock and 5,357,052 warrants to purchase shares of its common stock at an exercise price of $1.15 per share. The Rights Offering generated net proceeds to the Company of approximately $5.1 million after the payment of fees and expenses related to the Rights Offering. In connection with the closing of the Rights Offering, the Company issued a warrant to purchase 267,853 shares of common stock to Maxim Partners LLC, an affiliate of the dealer-manager of the Rights Offering.

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Note 12 - Stock-based Compensation On June 12, 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”) to replace the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). The 2018 Plan authorized the issuance of 1,000,000 shares of our common stock. In addition, up to 2,874,280 shares of our common stock currently reserved for issuance under the 2015 Plan became available for issuance under the 2018 Plan to the extent such shares were available for issuance under the 2015 Plan as of June 12, 2018 or cease to be subject to awards outstanding under the 2015 Plan, such as by expiration, cancellation, or forfeiture of such awards. The stock-based awards are generally issued with a price equal to no less than fair value at the date of grant. Options granted under the 2018 Plan generally vest immediately, or ratably over a two- to 36-month period coinciding with their respective service periods; however, participants may exercise their options prior to vesting as provided by the 2018 Plan. Unvested shares issued for options exercised early may be subject to a repurchase by the Company if the participant terminates, at the original exercise price. Options under the 2018 Plan generally have a contractual term of five years. Certain stock option awards provide for accelerated vesting upon a change in control. As of September 30, 2018, the Company had 1,860,375 shares of common stock available for issuance under the 2018 Plan. The Company measures the fair value of stock options with service-based and performance-based vesting criteria to employees, directors and consultants on the date of grant using the Black-Scholes option pricing model. The fair value of equity instruments issued to non-employees is re-measured as the award vests. The Black-Scholes valuation model requires the Company to make certain estimates and assumptions, including assumptions related to the expected price volatility of the Company’s stock, the period under which the options will be outstanding, the rate of return on risk-free investments, and the expected dividend yield for the Company’s stock. The weighted-average assumptions used in the Black-Scholes option-pricing model used to calculate the fair value of options granted during the nine months ended September 30, 2018, were as follows: Employee Non-Employee Expected volatility 71.0% -79.8 2% N/A Expected dividend yield — N/A Expected term (in years) 3.0-3.5 N/A Risk-free interest rate 1.58%-2.89 % N/A Due to the Company’s limited operating history and lack of company-specific historical or implied volatility, the expected volatility assumption was determined based on historical volatilities from traded options of biotech companies of comparable in size and stability, whose share prices are publicly available. The expected term of options granted to employees is calculated based on the mid-point between the vesting date and the end of the contractual term according to the simplified method as described in SEC Staff Accounting Bulletin 110 because the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its awards have been outstanding. For non-employee options, the expected term of options granted is the contractual term of the options. The risk-free rate by reference to the implied yields of U.S. Treasury securities with a remaining term equal to the expected term assumed at the time of grant. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends on its shares of capital stock. The table summarizes the stock option activity, for both the 2018 and the 2015 plans, for the periods indicated as follows: Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2017 1,651,800 $ 1.67 3.7 $ — Granted 173,471 $ 1.56 4.9 $ — Exercised (49,000 ) $ 0.50 — $ — Forfeited (50,500 ) $ — — $ — Expired — $ — — $ — Outstanding at September 30, 2018 1,725,771 $ 1.57 4.4 $ — Exercisable at September 30, 2018 1,436,050 $ 1.57 3.9 $ — (1) The aggregate intrinsic value on the table was calculated based on the difference between the estimated fair value of the Company’s stock and the exercise price of the underlying option. The estimated stock values used in the calculation was $0.69 and $0.72 per share for the nine months ended September 30, 2018 and the year ended December 31, 2017, respectively. The stock-based compensation expense was recorded as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development $ 29 $ 85 $ 87 $ 269 Selling, general and administrative 326 861 3,003 2,549 Total stock-based compensation expense $ 355 $ 946 $ 3,090 $ 2,818 The allocation between research and development and selling, general and administrative expense was based on the department and services performed by the employee or non-employee. At September 30, 2018, the total compensation cost related to unvested options not yet recognized was $989, which will be recognized over a weighted average period of 18 months, assuming the employees complete their service period required for vesting. Restricted Stock Units The following table summarizes restricted stock unit activity for the nine months ended September 30, 2018: Number of Units Weighted Average Grant-Date Fair Value Per Units Outstanding as of December 31, 2017 287,885 $ 1.86 Granted 75,732 $ 1.62 Vested (187,128 )(1) $ 2.56 Forfeited (3,577 ) $ 6.99 Outstanding as of September 30, 2018 172,912 $ 0.98 (1) In February 2018, the Company net issued 32,625 shares of common stock to a former employee of the Company under the employee’s separation agreement, which accelerated the vesting of certain restricted stock units.

License and Other Agreements

License and Other Agreements	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License and Other Agreements	Note 13 - License and Other Agreements Neogen Corporation On January 23, 2017 we entered into a termination agreement (the “Settlement Agreement”) with Neogen. Pursuant to the Settlement Agreement, the parties agreed to (a) terminate the existing Exclusive License Agreement between us and Neogen dated May 15, 2014 (the “License Agreement”), with neither Neogen or us having any further obligations thereunder (other than certain confidentiality obligations); (b) dismiss with prejudice the court action filed by Neogen in the District Court for the District of Arizona on January 19, 2017 (the “Court Action”), as further described below; and (c) mutually release any and all existing or future claims between the parties and their affiliates related to or arising from the License Agreement or the Court Action. As part of the Settlement Agreement, we agreed to pay to Neogen upon the execution of the Settlement Agreement an aggregate of $1.0 million in settlement of all claims. Bioceres/INMET S.A. Agreement In January 2016, the Company entered into a services agreement with Bioceres, Inc. (“Bioceres”), a wholly-owned subsidiary of Bioceres S.A., a leading agricultural biotechnology company in Argentina, and its Argentinean subsidiary, Ingenieria Metabolica S.A. (“INMET”) to develop a production method for synthetic triptolide, the main ingredient in ContraPest. The Company also entered into an agency agreement with INMET whereby the Company appointed INMET as its exclusive agent to seek regulatory approval for and conduct pre-sales and marketing of its product, ContraPest, in Argentina. The Company and INMET also agreed to manufacture and distribute its product in Argentina and other countries, as mutually agreed, through a newly formed entity. The initial term of the service agreement is for two years. The service agreement can be terminated at any time upon written notice by either party for any reason. The term of the agency agreement with INMET is the earlier of: (i) when the Company and INMET incorporate the joint venture entity in Argentina or (ii) January 2018. These agreements were renewed for an additional year, through January 2019.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 - Commitments and Contingencies Legal Proceedings The Company may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity. On February 20, 2018, New Enterprises, Ltd. (“New Enterprises”), filed suit in the U.S. District Court for the District of Arizona against the Company and Roth Capital Partners, LLC. The suit alleges nine counts against the Company, including that the Company engaged in common law fraud and securities fraud to induce the chairman of New Enterprises into investing in the Company; that the Company breached the lock-up agreement and tortiously interfered with prospective business advantage. New Enterprises is seeking monetary damages, including compensatory damages, punitive damages, and attorney’s fees. New Enterprises has also named Roth Capital Partners, LLC.as a co-defendant. Pursuant to our underwriting agreement with Roth Capital Partners, LLC., the Company may be required to indemnify Roth Capital Partners, LLC. for liabilities arising out of our initial public offering. The Company believes there is no basis to any of the claims, and intends to vigorously defend itself, including seeking appropriate counterclaims. Lease Commitments Rent expense was $183 and $246 for the nine months ended September 30, 2018 and September 30, 2017, respectively. The future minimum lease payments under non-cancellable operating lease and future minimum capital lease payments as of September 30, 2018 are as follows: Capital Leases Operating Lease Years Ending December 31, 2018 26 61 2019 99 221 2020 78 — 2021 63 — 2022 33 — 2023 3 — Total minimum lease payments $ 302 $ 282 Capital Leases Less: amounts representing interest (6.39%, ranging from 10.48% to 11.56%) $ 50 Present value of minimum lease payments 246 Less: current installments under capital lease obligations 77 Total long-term portion $ 169

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 15 - Subsequent Events In October 2018, the Company net issued 27,408 shares of common stock for the net settlement of restricted stock units that vested during the period. The shares of common stock withheld were used to satisfy required withholding tax liability in connection with the vesting of shares. The Company has evaluated subsequent events from the balance sheet date through November 13, 2018, the date at which the financial statements were issued, and determined that there were no other items that require adjustment to or disclosure in the financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in the Company’s financial statements include the valuation of preferred stock, common stock and related warrants, and other stock-based awards. Actual results could differ from such estimates.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no material impact on net earnings, financial position or cash flows.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers money market fund investments to be cash equivalents. The Company had such cash equivalents of $21 and $3 at September 30, 2018 and December 31, 2017, respectively, included in cash as reported.
Investments in Securities	Investments in Securities The Company uses cash holdings to purchase highly liquid, short term, investment grade securities diversified among security types, industries and issuers. All of the Company’s investment securities are measured at fair value. The Company’s investment securities primarily consist of municipal debt securities, corporate bonds, U.S. agency securities and commercial paper and highly-liquid money market funds.
Accounts Receivable	Accounts Receivable Accounts receivable consist entirely of trade receivables. The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. The allowance for doubtful trade receivables was less than $1 as of September 30, 2018 and $0 at December 31, 2017.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs consisted primarily of legal, accounting and other direct and incremental fees and costs related to the Rights Offering that closed on August 13, 2018 and the downward price adjustment that occurred to certain outstanding warrants as a result of the Rights Offering. Total deferred offering costs of $1.0 million were offset against the proceeds received from the Rights Offering during the quarter ending September 30, 2018. There were no deferred offering costs at September 30, 2018 or December 31, 2017.
Inventories	Inventories Inventories are stated at the lower of cost or market value, using the first-in, first-out convention. Inventories consist of raw materials, work in process and finished goods.
Prepaid Expenses	Prepaid Expenses Prepaid expenses consist primarily of payments made for director compensation as well as payments made for director and officer insurance, rent and legal deposits to be expensed in the current year.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Equipment held under capital leases are stated at the present value of minimum lease payments less accumulated amortization. Depreciation on property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. The cost of leasehold improvements is amortized over the life of the improvement or the term of the lease, whichever is shorter. Equipment held under capital leases is amortized over the shorter of the lease term or estimated useful life of the asset. The Company incurs repair and maintenance costs on its major equipment, which are expensed as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require long-lived assets or asset groups to be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated from the use of the asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, such as discounted cash flow models and the use of third-party independent appraisals. The Company has not recorded an impairment of long-lived assets since its inception.
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Revenue Recognition. Revenue Recognition The Company recognizes revenue when it leaves their facility at a fixed selling price and payment terms of 30 to 60 days from invoicing. All of the revenue recognized in the three month and nine month periods ended September 30, 2018 and 2017 is from the sale of Contrapest.
Research and Development	Research and Development Research and development costs are expensed as incurred. Research and development expenses primarily consist of salaries and benefits for research and development employees, stock-based compensation, consulting fees, lab supplies, costs incurred related to conducting scientific trials and field studies, and regulatory compliance costs. Also, included in research and development expenses is an allocation of facilities related costs, including depreciation of research and development equipment.
Stock-based Compensation	Stock-based Compensation Employee stock-based awards, consisting of restricted stock units and stock options expected to be settled in shares of the Company’s common stock, are recorded as equity awards. The grant date fair value of these awards is measured using the Black-Scholes option pricing model. The Company expenses the grant date fair value of its stock options on a straight-line basis over their respective vesting periods. Performance-based awards are expensed over the performance period when the related performance goals are probable of being achieved. For equity instruments issued to non-employees, the stock-based consideration is measured using a fair value method. The measurement of the stock-based compensation is subject to re-measurement as the underlying equity instruments vest. The stock-based compensation expense recorded for the three and nine months ended September 30, 2018 and 2017, is as follows: Three Months Ended Nine Months Ended 2018 2017 2018 2017 Research and development $ 29 $ 85 $ 87 $ 269 Selling, general and administrative 326 861 3,003 2,549 Total stock-based compensation expense $ 355 $ 946 $ 3,090 $ 2,818 See Note 13 for additional discussion on stock-based compensation.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities and net operating loss carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. The Company records net deferred tax assets to the extent it believes these assets will more likely than not be realized. These deferred tax assets are subject to periodic assessments as to recoverability and if it is determined that it is more likely than not that the benefits will not be realized, valuation allowances are recorded which would increase the provision for income taxes. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. The Company applies a more-likely-than-not recognition threshold for all tax uncertainties. Only those benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities are recognized. Based on its evaluation, the Company has concluded there are no significant uncertain tax positions requiring recognition in its financial statements. The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There are no uncertain tax positions as of September 30, 2018 or December 31, 2017 and as such, no interest or penalties were recorded in income tax expense. On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) which provides guidance on accounting for the tax effects of the Tax Cuts and Job Act of 2017 (the “Tax Act”). SAB 118 provides a measurement period that should not extend beyond one year from the date of enactment for companies to complete the accounting under ASC 740, Income Taxes. The Company is still analyzing the Tax Act and the impact, if any, it will have.
Comprehensive Loss	Comprehensive Loss Net loss and comprehensive loss were the same for all periods presented; therefore, a separate statement of comprehensive loss is not included in the accompanying financial statements.
Loss Per Share Attributable to Common Stockholders	Loss Per Share Attributable to Common Stockholders Basic loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per share attributable to common stockholders is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods. For purposes of the computation of diluted loss per share attributable to common stockholders, common stock purchase warrants, and common stock options are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share attributable to common stockholders because their effect would be anti-dilutive given the net loss reported for the three and nine months ended September 30, 2018 and 2017. Therefore, basic and diluted loss per share attributable to common stockholders are the same for each period presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted loss per share attributable to common stockholders (in common stock equivalent shares): September 30, 2018 2017 Common stock purchase warrants 11,714,940 829,285 Restricted stock units 172,912 344,982 Common stock options 1,725,771 1,558,800 Total 13,613,623 2,733,067
Adoption of New Accounting Standards	Adoption of New Accounting Standards: In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers “Revenue from Contracts with Customers” Revenue Recognition In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities
Accounting Standards Issued But Not Yet Adopted:	Accounting Standards Issued But Not Yet Adopted: In February 2016, the FASB issued ASU 2016-02, Leases

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of employee stock-based compensation expense	The stock-based compensation expense recorded for the three and nine months ended September 30, 2018 and 2017, is as follows: Three Months Ended Nine Months Ended 2018 2017 2018 2017 Research and development $ 29 $ 85 $ 87 $ 269 Selling, general and administrative 326 861 3,003 2,549 Total stock-based compensation expense $ 355 $ 946 $ 3,090 $ 2,818
Schedule of outstanding potentially dilutive securities calculation of diluted loss per share attributable to common stockholders	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted loss per share attributable to common stockholders (in common stock equivalent shares): September 30, 2018 2017 Common stock purchase warrants 11,714,940 829,285 Restricted stock units 172,912 344,982 Common stock options 1,725,771 1,558,800 Total 13,613,623 2,733,067

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of fair value on a recurring basis by level of fair value hierarchy	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy: September 30, 2018 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 21 $ — $ — $ 21 Corporate fixed income debt securities — 2,448 — 2,448 Total $ 21 $ 2,448 $ — $ 2,469 Financial Liabilities: Common stock warrant liability (1) $ — $ — $ — $ — Total $ — $ — $ — $ — December 31, 2017 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 3 $ — $ — $ 3 Corporate fixed income debt securities — 5,023 — 5,023 Total $ 3 $ 5,023 $ — $ 5,026 Financial Liabilities: Common stock warrant liability (1) $ — $ — $ — $ — Total $ — $ — $ — $ — (1) The change in the fair value of the common stock warrant and convertible notes payable for the three and nine months ended September 30, 2018 was recorded as a decrease to other income (expense) and interest expense of $1 and $1, respectively, in the statements of operations and comprehensive loss.

Investments in Securities (Tab

Investments in Securities (Tables)	9 Months Ended
	Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]
Summary of investment in securities	The following is a summary of investment in securities at September 30, 2018: September 30, 2018 Contractual Maturity (in months) Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Mutual funds $ — $ — $ — $ — Corporate fixed income securities Less than 12 months 2,447 1 — 2,448 Total investments $ 2,447 $ 1 $ — $ 2,448

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses	Prepaid expenses consist of the following: September 30, December 31, 2018 2017 Director compensation $ 156 $ 66 Director and officer insurance 102 33 NASDAQ fees 14 — Legal retainer 25 25 Inventory purchase deposits 20 20 Professional services retainer 8 8 Equipment service deposits 5 7 Engineering, software licenses and other 6 11 Total prepaid expenses $ 336 $ 170

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment, net consist of the following: Useful September 30, December 31, Life 2018 2017 Research and development equipment 5 years $ 1,540 $ 1,349 Office and computer equipment 3 years 730 672 Autos 5 years 54 305 Furniture and fixtures 7 years 34 34 Leasehold improvements * 283 283 2,641 2,643 Less accumulated depreciation (1,470 ) (1,189 ) Total $ 1,171 $ 1,454 * Shorter of lease term or estimated useful life

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Schedule of accrued expenses	Accrued expenses consist of the following: September 30, December 31, 2018 2017 Compensation and related benefits $ 217 $ 304 Accrued Litigation 269 269 Board Compensation — 16 Stock service fees 23 — Delaware Franchise Tax-Other 22 — Total accrued expenses $ 531 $ 589

Borrowings (Tables)

Borrowings (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of capital lease obligations	A summary of the Company’s borrowings, including capital lease obligations, is as follows: September 30, December 31, Short-term debt: 2018 2017 Current portion of long-term debt 235 177 Total short-term debt $ 235 $ 177 Long-term debt: Capital lease obligations $ 252 $ 272 Other promissory notes 279 496 Total 531 768 Less: current portion of long-term debt (235 ) (177 ) Total long-term debt $ 296 $ 591

Notes Payable, Related Parties

Notes Payable, Related Parties (Tables)	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Schedule of notes payable, related parties	A summary of the Company’s notes payable, related parties is as follows: September 30, December 31, 2018 2017 Unsecured promissory note, interest rate of 4.25% and 8% per annum $ 0 $ 12 Total notes payable, related parties 0 12 Less: current portion of notes payable, related parties 0 12 Total notes payable, long-term $ — $ —

Common Stock Warrants and Com_2

Common Stock Warrants and Common Stock Warrant Liability (Tables)	9 Months Ended
	Sep. 30, 2018
Warrants and Rights Note Disclosure [Abstract]
Schedule of common stock warrant activity	The table summarizes the common stock warrant activity as of September 30, 2018 as follows: Number of Date Exercise Common Stock Warrants Warrants Issued Term Price Outstanding at December 31, 2016 829,285 Common Stock Offering Warrants Issued 4,657,500 November 2017 5 years $ 1.50 (1) Common Stock Offering Underwriter Warrants 945,000 November 2017 5 years $ 1.50 Outstanding at December 31, 2017 6,431,785 Warrants issued 1,133,909 June 2018 5 years $ 1.82 Common Stock Offering Warrants Issued 5,357,052 August 2018 5 years $ 1.15 (1) Common Stock Offering - Dealer Manager Warrants 267,853 August 2018 5 years $ 1.725 Warrants exercised (1,475,659) Outstanding at September 30, 2018 11,714,940 (1) The common stock warrants issued in November 2017 with an initial exercise price of $1.50 per share adjusted downward to $0.95 per share effective July 24, 2018 in connection with our Rights Offering, and may be subject to further downward adjustments, pursuant to antidilution price adjustment protection contained within those warrants.

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of fair value of options granted	The weighted-average assumptions used in the Black-Scholes option-pricing model used to calculate the fair value of options granted during the nine months ended September 30, 2018, were as follows: Employee Non-Employee Expected volatility 71.0% -79.8 2% N/A Expected dividend yield — N/A Expected term (in years) 3.0-3.5 N/A Risk-free interest rate 1.58%-2.89 % N/A
Schedule of stock option activity	The table summarizes the stock option activity, for both the 2018 and the 2015 plans, for the periods indicated as follows: Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2017 1,651,800 $ 1.67 3.7 $ — Granted 173,471 $ 1.56 4.9 $ — Exercised (49,000 ) $ 0.50 — $ — Forfeited (50,500 ) $ — — $ — Expired — $ — — $ — Outstanding at September 30, 2018 1,725,771 $ 1.57 4.4 $ — Exercisable at September 30, 2018 1,436,050 $ 1.57 3.9 $ — (1) The aggregate intrinsic value on the table was calculated based on the difference between the estimated fair value of the Company’s stock and the exercise price of the underlying option. The estimated stock values used in the calculation was $0.69 and $0.72 per share for the nine months ended September 30, 2018 and the year ended December 31, 2017, respectively.
Schedule of stock-based compensation expense	The stock-based compensation expense was recorded as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development $ 29 $ 85 $ 87 $ 269 Selling, general and administrative 326 861 3,003 2,549 Total stock-based compensation expense $ 355 $ 946 $ 3,090 $ 2,818
Schedule of summarizes restricted stock unit activity [Table Text Block]	The following table summarizes restricted stock unit activity for the nine months ended September 30, 2018: Number of Units Weighted Average Grant-Date Fair Value Per Units Outstanding as of December 31, 2017 287,885 $ 1.86 Granted 75,732 $ 1.62 Vested (187,128 )(1) $ 2.56 Forfeited (3,577 ) $ 6.99 Outstanding as of September 30, 2018 172,912 $ 0.98 (1) In February 2018, the Company net issued 32,625 shares of common stock to a former employee of the Company under the employee’s separation agreement, which accelerated the vesting of certain restricted stock units.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of the future minimum lease payments under non-cancellable operating lease and future minimum capital lease payments	Rent expense was $183 and $246 for the nine months ended September 30, 2018 and September 30, 2017, respectively. The future minimum lease payments under non-cancellable operating lease and future minimum capital lease payments as of September 30, 2018 are as follows: Capital Leases Operating Lease Years Ending December 31, 2018 26 61 2019 99 221 2020 78 — 2021 63 — 2022 33 — 2023 3 — Total minimum lease payments $ 302 $ 282 Capital Leases Less: amounts representing interest (6.39%, ranging from 10.48% to 11.56%) $ 50 Present value of minimum lease payments 246 Less: current installments under capital lease obligations 77 Total long-term portion $ 169

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Aug. 31, 2018	Aug. 13, 2018	Sep. 30, 2018	Dec. 31, 2017	Jun. 01, 2018	Nov. 30, 2017	Nov. 21, 2017	Dec. 08, 2016
Proceeds from the exercise of warrants			$ 2,213
Proceeds from issuance and sale of common stock, preferred stock, warrants exercise, convertible and other promissory notes			61,700
Proceeds from licensing fees			1,700
Proceeds from product sales			200
Accumulated deficit			(83,208)	$ (73,597)
Cash, cash equivalents and short-term investments			$ 7,200
Common Stock Offering Warrants Issued
Initial Public Offering [Member]
Number of shares issued								1,875,000
Initial Public Offering [Member] | Common Stock Purchase Warrants [Member]
Number of shares issued								187,500
exercise price (in dollars per share)								$ 9.60
Public Offering [Member]
Number of shares issued							5,860,000
Shares issued per share (in dollars per share)							$ 1
Public Offering [Member] | Common Stock Purchase Warrants [Member] | Investor [Member]
Number of shares issued							4,657,500
exercise price (in dollars per share)							$ 1.50
Public Offering [Member] | Common Stock Purchase Warrants [Member] | Roth Capital Partners, LLC [Member]
Number of shares issued							945,000
exercise price (in dollars per share)							$ 1.50
Private placement [Member] | Common Stock Purchase Warrants [Member]
Number of shares issued					1,133,909	1,133,909
exercise price (in dollars per share)					$ 1.82	$ 1.50
Right Offering [Member]
exercise price (in dollars per share)	$ 1.15	$ 1.15
Unit price (in dollars per unit)	1.15	$ 1.15
Number of subscriptions shares accept		5,357,052
Common Stock Offering Warrants Issued		5,357,052
Right Offering [Member] | Common Stock Purchase Warrants [Member] | Maxim Partners LLC [Member]
exercise price (in dollars per share)	$ 1.725	$ 1.725
Number of subscriptions shares accept	5,357,052
Common Stock Offering Warrants Issued	267,853	267,853

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total stock-based compensation expense	$ 355	$ 946	$ 3,090	$ 2,818
Research and Development Expense [Member]
Total stock-based compensation expense	29	85	87	269
Selling, General and Administrative Expenses [Member]
Total stock-based compensation expense	$ 326	$ 861	$ 3,003	$ 2,549

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Total	13,613,623	2,733,067
Common Stock Purchase Warrants [Member]
Total	11,714,940	829,285
Restricted Stock Units [Member]
Total	172,912	344,982
Common stock options [Member]
Total	1,725,771	1,558,800

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Cash equivalents, at carrying value	$ 21		$ 21		$ 3
Allowance for doubtful trade receivables	1		1		$ 0
Net revenues	105	$ 17	160	$ 34
Future minimum lease payments	282		282
Rights Offering [Member]
Deferred offering costs	$ 1,000		$ 1,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands		Sep. 30, 2018	Dec. 31, 2017
Financial Assets:
Held-to-maturity Securities, Fair Value		$ 2,448
Fair Value Measurements, Recurring [Member]
Financial Assets:
Total		2,469	$ 5,026
Financial Liabilities:
Total
Fair Value Measurements, Recurring [Member] | Corporate Fixed Income Debt Securities [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		2,448	5,023
Fair Value Measurements, Recurring [Member] | Money Market Funds [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		21	3
Financial Liabilities:
Common stock warrant liability	[1]
Fair Value Measurements, Recurring [Member] | Fair Value Inputs, Level 1 [Member]
Financial Assets:
Total		21	3
Financial Liabilities:
Total
Fair Value Measurements, Recurring [Member] | Fair Value Inputs, Level 1 [Member] | Corporate Fixed Income Debt Securities [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value
Fair Value Measurements, Recurring [Member] | Fair Value Inputs, Level 1 [Member] | Money Market Funds [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		21	3
Financial Liabilities:
Common stock warrant liability	[1]
Fair Value Measurements, Recurring [Member] | Fair Value Inputs, Level 2 [Member]
Financial Assets:
Total		2,448	5,023
Financial Liabilities:
Total
Fair Value Measurements, Recurring [Member] | Fair Value Inputs, Level 2 [Member] | Corporate Fixed Income Debt Securities [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value		2,448	5,023
Fair Value Measurements, Recurring [Member] | Fair Value Inputs, Level 2 [Member] | Money Market Funds [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value
Financial Liabilities:
Common stock warrant liability	[1]
Fair Value Measurements, Recurring [Member] | Fair Value Inputs, Level 3 [Member]
Financial Assets:
Total
Financial Liabilities:
Total
Fair Value Measurements, Recurring [Member] | Fair Value Inputs, Level 3 [Member] | Corporate Fixed Income Debt Securities [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value
Fair Value Measurements, Recurring [Member] | Fair Value Inputs, Level 3 [Member] | Money Market Funds [Member]
Financial Assets:
Held-to-maturity Securities, Fair Value
Financial Liabilities:
Common stock warrant liability	[1]
[1]	The change in the fair value of the common stock warrant and convertible notes payable for the three and nine months ended September 30, 2018 was recorded as a decrease to other income (expense) and interest expense of $1 and $1, respectively, in the statements of operations and comprehensive loss.

Fair Value Measurements (Deta_2

Fair Value Measurements (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair value adjustment of warrants	$ 1	$ 1

Investments in Securities (Deta

Investments in Securities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Schedule of Held-to-maturity Securities [Line Items]
Cost	$ 2,447
Gross Unrealized Gains	1
Gross Unrealized Losses
Fair Market Value	2,448
Corporate Fixed Income Securities [Member]
Schedule of Held-to-maturity Securities [Line Items]
Cost	2,447
Gross Unrealized Gains	1
Gross Unrealized Losses
Fair Market Value	$ 2,448
Description Contractual Maturity	Less than 12 months</p>" id="sjs-B14">&lt;p style="margin-top: 0pt; margin-bottom: 0pt">Less than 12 months&lt;/p>
Mutual Funds [Member]
Schedule of Held-to-maturity Securities [Line Items]
Cost
Gross Unrealized Gains
Gross Unrealized Losses
Fair Market Value

Investments in Securities (De_2

Investments in Securities (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]
Net gain (loss) on investents	$ 12	$ 44

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Director compensation	$ 156	$ 66
Director and officer insurance	102	33
NASDAQ fees	14
Legal retainer	25	25
Inventory purchase deposits	20	20
Professional services retainer	8	8
Equipment service deposits	5	7
Engineering, software licenses and other	6	11
Total prepaid expenses	$ 336	$ 170

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment, Gross		$ 2,641	$ 2,643
Less accumulated depreciation		(1,470)	(1,189)
Total		1,171	1,454
Research and Development Equipment [Member]
Property, Plant and Equipment, Gross		$ 1,540	1,349
Property, Plant and Equipment, Useful Life		5 years
Office and Computer Equipment [Member]
Property, Plant and Equipment, Gross		$ 730	672
Property, Plant and Equipment, Useful Life		3 years
Autos [Member]
Property, Plant and Equipment, Gross		$ 54	305
Property, Plant and Equipment, Useful Life		5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross		$ 34	34
Property, Plant and Equipment, Useful Life		7 years
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	[1]	$ 283	283
Construction In Process [Member]
Property, Plant and Equipment, Gross
[1]	Shorter of lease term or estimated useful life

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 108	$ 118	$ 332	$ 273

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Compensation and related benefits	$ 217	$ 304
Accrued Litigation	269	269
Board Compensation		16
Stock service fees	23
Delaware Franchise Tax-Other	22
Total accrued expenses	$ 531	$ 589

Borrowings (Details)

Borrowings (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Short-term debt:
Current portion of long-term debt	$ 235	$ 177
Total short-term debt	235	177
Long-term debt:
Capital lease obligations	252	272
Other promissory notes	279	496
Total	531	768
Less: current portion of long-term debt	(235)	(177)
Total long-term debt	$ 296	$ 591

Borrowings (Details Narrative)

Borrowings (Details Narrative)	9 Months Ended
	Sep. 30, 2018
Other Promissory Notes [Member]
Description of borrowings expiration period	Various dates through June 2022
Other Promissory Notes [Member] | Maximum [Member]
Interest rate on borrowings	13.80%
Other Promissory Notes [Member] | Minimum [Member]
Interest rate on borrowings	4.30%
Capital Lease Obligations [Member]
Description of borrowings expiration period	Various dates through July 2023
Capital Lease Obligations [Member] | Maximum [Member]
Interest rate on borrowings	11.60%
Capital Lease Obligations [Member] | Minimum [Member]
Interest rate on borrowings	6.00%

Notes Payable, Related Partie_2

Notes Payable, Related Parties (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Related Party Transactions [Abstract]
Unsecured promissory note, interest rate of 4.25% and 8% per annum	$ 0	$ 12
Total notes payable, related parties	0	12
Less: current portion of notes payable, related parties	0	12
Total notes payable, long-term

Notes Payable, Related Partie_3

Notes Payable, Related Parties (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 30, 2013	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Settlement of outstanding obligations	$ 40	$ 0		$ 0		$ 12
Due to Employees	$ 72
Interest expense related party					$ 1	$ 1
Salary Obligation [Member]
Debt interest rate	4.25%
Debt instrument payment	$ 1
Debt instrument maturity date	Jun. 30, 2018
Unsecured Promissory Note [Member]
Debt interest rate	8.00%
Debt instrument payment	$ 1
Debt instrument maturity date	May 31, 2018

Common Stock Warrants and Com_3

Common Stock Warrants and Common Stock Warrant Liability (Details) - $ / shares		9 Months Ended	12 Months Ended
		Sep. 30, 2018	Dec. 31, 2017
Outstanding at beginning		6,431,785	829,285
Warrants issued
Warrants exercised		(1,475,659)
Outstanding at end		11,714,940	6,431,785
Warrants issued [Member]
Warrants issued		1,133,909
Date Issued		2018-06
Term		5 years
Exercise Price (in dollars per share)		$ 1.82
Common Stock Offering Warrants Issued [Member]
Warrants issued		5,357,052	4,657,500
Date Issued		2018-08	2017-11
Term		5 years	5 years
Exercise Price (in dollars per share)	[1]	$ 1.15	$ 1.50
Common Stock Offering - Dealer Manager Warrants [Member]
Warrants issued		267,853
Date Issued		2018-08
Term		5 years
Exercise Price (in dollars per share)		$ 1.725
Common Stock Offering Underwriter Warrants [Member]
Warrants issued			945,000
Date Issued			2017-11
Term			5 years
Exercise Price (in dollars per share)			$ 1.50
[1]	The common stock warrants issued in November 2017 with an initial exercise price of $1.50 per share adjusted downward to $0.95 per share effective July 24, 2018 in connection with our Rights Offering, and may be subject to further downward adjustments, pursuant to antidilution price adjustment protection contained within those warrants.

Common Stock Warrants and Com_4

Common Stock Warrants and Common Stock Warrant Liability (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Sep. 13, 2018	Aug. 31, 2018	Aug. 13, 2018	Jul. 24, 2018	Jun. 20, 2018	Nov. 21, 2017	Jun. 30, 2018	Nov. 30, 2017	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jun. 30, 2015
Warrants exercised										(1,475,659)
Common Stock Offering Warrants Issued
Share price (in dollars per share)									$ 0.69	$ 0.69		$ 0.72
Fair value adjustment of warrants									$ 1	$ 1
Proceeds from warrant exercises										2,213
Stock compensation expense										$ 3,090	$ 2,818
Number of share issued in transaction										1,475,659
Deemed dividend										$ 333
Unexercised warrants										$ 3,181,841
Common Stock Warrants Issued To Participants in Offering of the Company's Common Stock [Member]
Common Stock Offering Warrants Issued					1,133,909
Number of shares purchased					1,133,909	4,657,500			1,133,909	1,133,909
Exercise price (in dollars per share)					$ 1.50	$ 1.50			$ 1.82	$ 1.82
Warrant term						5 years
Description of method used						Lattice model
Share price (in dollars per share)						$ 1			2.11	2.11
Fair value of common stock warrant						$ 661
Expected volatility rate						73.80%	72.60%
Expected term						5 years	5 years
Expected dividend rate						0.00%	0.00%
Risk free interest rate						1.87%	2.80%
Proceeds from warrant exercises					$ 1,700		$ 1,700
Stock compensation expense							1,700
Common Stock Warrant Issued to Underwriter of Common Stock Offering [Member]
Number of shares purchased								945,000
Exercise price (in dollars per share)			$ 0.95	$ 1.47				$ 1.50
Warrant term								5 years
Description of method used								Lattice model
Share price (in dollars per share)			$ 1.02	$ 1.38				$ 1
Fair value of common stock warrant								$ 134
Expected volatility rate			74.00%	72.40%				73.80%
Expected term			4 years 3 months	4 years 3 months 29 days				5 years
Expected dividend rate			0.00%	0.00%				0.00%
Risk free interest rate			2.75%	2.83%				1.87%
University of Arizona Common Stock Warrant [Member]
Number of shares purchased													15,000
Exercise price (in dollars per share)									$ 7.91	$ 7.91			$ 7.50
Warrant term										5 years
Description of method used										Monte Carlo option pricing model
Expected volatility rate										77.70%
Expected dividend rate										0.00%
Risk free interest rate										1.93%
Derivative liability									$ 0	$ 0			$ 53
New Warrants November 8, 2017 [Member]
Number of shares purchased					1,133,909				341,750	341,750
Exercise price (in dollars per share)					$ 1.82
Proceeds from warrant exercises							$ 513
Right Offering [Member]
Common Stock Offering Warrants Issued			5,357,052
Exercise price (in dollars per share)		$ 1.15	$ 1.15
Share price (in dollars per share)			$ 0.94
Fair value of common stock warrant			$ 3,600
Expected volatility rate	159.00%
Expected term	5 years
Expected dividend rate	0.00%
Risk free interest rate	2.77%
Number of share issued in transaction			5,357,052
Right Offering [Member] | Common Stock Purchase Warrants [Member] | Maxim Partners LLC [Member]
Common Stock Offering Warrants Issued		267,853	267,853
Exercise price (in dollars per share)		$ 1.725	$ 1.725
Share price (in dollars per share)			$ 0.94
Fair value of common stock warrant			$ 70
Expected volatility rate			159.00%
Expected term			5 years
Expected dividend rate			0.00%
Risk free interest rate			2.77%
Second Public Offering [Member]
Number of shares purchased						5,860,000
Exercise price (in dollars per share)						$ 1

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Aug. 31, 2018	Aug. 13, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Common stock, shares, issued			23,425,237		16,404,195
Common stock, shares, outstanding			23,425,237		16,404,195
Aggregate number of common stock issued			7,021,092
Proceeds from issuance of common stock			$ 5,132
Cashless exercise of vested stock options			(49,000)
Warrants exercised			(1,475,659)
Proceeds from the exercise of warrants			$ 2,213
Number of units issued in transaction			1,475,659
Common stock, par value (in dollars per share)			$ 0.001		$ 0.001
Common Stock Offering Warrants Issued
Former Employee [Member]
Number of restricted stock units vested during the period			32,625
Board Member [Member]
Number of restricted stock units vested during the period			37,162
Settlement of compensation			$ 28
Restricted Stock Units [Member]
Cashless exercise of vested stock options			13,900
Number of restricted stock units vested during the period			104,694
Right Offering [Member]
Value of common stock issued			$ 5,357,052
Proceeds from issuance of common stock			$ 5,100
Number of subscriptions shares accept		5,357,052
Number of units issued in transaction		5,357,052
Unit price (in dollars per unit)	$ 1.15	$ 1.15
Exercise price (in dollars per share)	$ 1.15	1.15
Common stock, par value (in dollars per share)		$ 0.001
Common Stock Offering Warrants Issued		5,357,052
Right Offering [Member] | Common Stock Purchase Warrants [Member] | Maxim Partners LLC [Member]
Number of subscriptions shares accept	5,357,052
Exercise price (in dollars per share)	$ 1.725	$ 1.725
Common Stock Offering Warrants Issued	267,853	267,853

Stock-based Compensation (Detai

Stock-based Compensation (Details) - Employee [Member]	9 Months Ended
	Sep. 30, 2018
Expected volatility, Minimum	71.00%
Expected volatility, Maximum	79.80%
Expected dividend yield
Expected term (in years)	3 years 6 months
Risk-free interest rate, Minimum	1.58%
Risk-free interest rate, Maximum	2.89%

Stock-based Compensation (Det_2

Stock-based Compensation (Details 1)	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning | shares	1,651,800
Granted | shares	173,471
Exercised | shares	(49,000)
Forfeited | shares	(50,500)
Expired | shares
Outstanding at ending | shares	1,725,771
Exercisable at ending | shares	1,436,050
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning | $ / shares	$ 1.67
Granted | $ / shares	1.56
Exercised | $ / shares	0.50
Forfeited | $ / shares
Expired | $ / shares
Outstanding at ending | $ / shares	1.57
Exercisable at ending | $ / shares	$ 1.57
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Life [Roll Forward]
Outstanding at beginning	3 years 8 months 12 days
Granted	4 years 10 months 24 days
Outstanding at ending	4 years 4 months 24 days
Exercisable at ending	3 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]
Outstanding at ending | $		[1]
Exercisable at ending | $		[1]
[1]	The aggregate intrinsic value on the table was calculated based on the difference between the estimated fair value of the Company's stock and the exercise price of the underlying option. The estimated stock values used in the calculation was $0.69 and $0.72 per share for the nine months ended September 30, 2018 and the year ended December 31, 2017, respectively.

Stock-based Compensation (Det_3

Stock-based Compensation (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Allocated Share-based Compensation Expense	$ 355	$ 946	$ 3,090	$ 2,818
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	29	85	87	269
Selling, General and Administrative Expenses [Member]
Allocated Share-based Compensation Expense	$ 326	$ 861	$ 3,003	$ 2,549

Stock-based Compensation (Det_4

Stock-based Compensation (Details 3) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Balance at beginning | shares	287,885
Granted | shares	75,732
Vested | shares	(187,128)	[1]
Forfeited | shares	(3,577)
Balance at ending | shares	172,912
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Balance at beginning | $ / shares	$ 1.86
Granted | $ / shares	1.62
Vested | $ / shares	2.56
Forfeited | $ / shares	6.99
Balance at ending | $ / shares	$ 0.98
[1]	In February 2018, the Company net issued 32,625 shares of common stock to a former employee of the Company under the employee?s separation agreement, which accelerated the vesting of certain restricted stock units.

Stock-based Compensation (Det_5

Stock-based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jul. 12, 2018	Feb. 28, 2018	Sep. 30, 2018	Dec. 31, 2017
Share price			$ 0.69	$ 0.72
Aggregate number of common stock issued			7,021,092
Equity Incentive Plan 2018 [Member]
Number of shares authorized	1,000,000
Number of additional shares authorized	2,874,280
Common stock capital shares reserved for future issuance			1,860,375
Stock Option Plan 2008-2009 [Member]
Compensation cost not yet recognized			$ 989
Restricted Stock Units [Member] | Employee's Separation Agreement [Member]
Aggregate number of common stock issued		32,625

License and Other Agreements (D

License and Other Agreements (Details Narrative) $ in Thousands	1 Months Ended
	Jan. 23, 2017USD ($)
Neogen Corporation [Member]
Litigation settlement, amount	$ 1,000

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Capital Leases
2,018	$ 26
2,019	99
2,020	78
2,021	63
2,022	33
2,023	3
Total minimum lease payments	302
Operating Lease
2,018	61
2,019	221
2,020
2,021
2,022
2,023
Total minimum lease payments	282
Less: amounts representing interest (6.39%, ranging from 10.48% to 11.56%)	50
Present value of minimum lease payments	246
Less: current installments under capital lease obligations	77
Total long-term portion	$ 252	$ 272

Commitments and Contingencies_3

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 183	$ 246

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - shares	1 Months Ended	9 Months Ended
	Oct. 31, 2018	Sep. 30, 2018
Subsequent Event [Line Items]
Number of shares issued		7,021,092
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares issued	27,408